Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. - Wikidata - awgldk - TriplyDB

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

http://www.wikidata.org/entity/Q35453691

about

Radiotherapy combination opportunities leveraging immunity for the next oncology practice Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines Neoantigen-based cancer immunotherapy Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer Improving the clinical impact of biomaterials in cancer immunotherapy.Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity Novel technologies and emerging biomarkers for personalized cancer immunotherapy Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies Immune responses to human cancer stem-like cells/cancer-initiating cells Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine Next-generation sequencing to guide cancer therapy Overcoming T cell exhaustion in infection and cancer αβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapy PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.High-content molecular profiling of T-cell therapy in oncology Recent advances in understanding antitumor immunity Tumor neoantigens: building a framework for personalized cancer immunotherapy PD-L1 and Survival in Solid Tumors: A Meta-Analysis Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer Engineering New Approaches to Cancer Vaccines From mice to humans: developments in cancer immunoediting POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer PD-1 Blockade in Tumors with Mismatch-Repair Deficiency A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions.TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.Citizens unite for computational immunology!PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors.Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.Neoantigens in cancer immunotherapy.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

P2860

Q26738443-742941C9-0C16-4BA5-B325-24BC945D1F4A Q26738680-717CA710-A475-47C8-958B-88AF7FF1EAFA Q26738693-6CAE8164-42D1-46AF-ACBD-C3154257C05F Q26752491-74D07965-3D51-4AEE-BF8B-5C8D23A05EF3 Q26766267-BDEE79D3-E8CF-47B5-A57F-17B08D7F467E Q26769044-A7B3A3CE-B29A-42A3-945A-7E46E4203015 Q26769744-C5ABB040-0915-454E-8F1E-6B16A095B197 Q26770780-1527D596-E8A1-41A6-AF1D-FC342673693D Q26774312-B00CD151-40F7-4574-B09D-B05AC31AC017 Q26776184-61233705-564F-4416-ABCF-70E5541E97F8 Q26781794-BB65F0CB-83BF-42FA-B864-CA85DE650EBA Q26782583-6E080EB0-DC6B-4194-B81B-B3CB10232D66 Q26801946-9ECB32DD-039E-4500-AC92-4D7D669EA4EC Q26829885-3E0EB98A-A1BB-45CE-8A30-E84D1329402B Q26861133-8F6FE6FE-DB64-40DA-ADC2-0A689E51E9D2 Q27313748-0B4A3371-8B52-48EB-ABF2-F4042498D470 Q27316403-11009174-154E-4BFA-9945-36316845FB30 Q27853176-4BDAC13C-83DC-4892-8882-B3B42F72DCA7 Q27853331-B01D1545-85BD-4EFB-B1E8-1CA45B73707E Q28066792-B21956E3-2FF0-4833-82B9-336B9E0688D0 Q28067217-488562F2-F277-4FB9-8385-F75A0140C8F3 Q28082704-C27F920F-E579-423B-A077-6F4D5929D74A Q28084090-B8D2DD96-2E25-4C78-9FAF-7FA0659DDCC4 Q28084766-3715AB97-5CE1-4A33-A07A-E1D8CD03786D Q28085563-F06A01DB-837A-471C-A6C1-F98F06EB87A9 Q28088304-4EBDB0FB-B76A-4069-8025-C090E5B39F56 Q28260529-EC1EE8CE-255E-4471-8BB9-B7C7CD822134 Q28262647-A13DDFDE-4B95-4F2B-9A4B-1FFB10F98080 Q28550391-D3D3E99A-3E48-4CF5-A2E3-D280897F1100 Q29615679-13804803-205B-468D-B49F-604711FC3018 Q30277192-69CE7EBB-085F-4B53-ABC8-6264236D3700 Q30391717-875EBD1A-90A0-423C-8802-C81676545157 Q30668579-DFC08CCD-90A5-4133-A9C0-B567E1D920E2 Q31148562-9C9C261E-89A3-4535-9FC7-A14BF5AB7F64 Q33361064-9E8CC7DA-0854-4C57-A3C9-283DBFB71C4D Q33785947-E21640F3-EC22-459A-A1D8-8FFD7D5EC4F6 Q33788685-8D3B99E6-C7D8-44CF-BC4E-8A2B327AA15A Q33806351-B8D2FF76-767A-48EB-B097-590E7DB38B6E Q34470074-91718DAF-321D-42F8-A45C-B41864DF9552 Q34522172-5360206C-7FFF-40FA-8C88-E95AF8B1503E

P2860

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

http://www.wikidata.org/entity/Q35453691

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Predicting immunogenic tumour ...... trometry and exome sequencing.

@ast

Predicting immunogenic tumour ...... trometry and exome sequencing.

@en

type

label

Predicting immunogenic tumour ...... trometry and exome sequencing.

@ast

Predicting immunogenic tumour ...... trometry and exome sequencing.

@en

prefLabel

Predicting immunogenic tumour ...... trometry and exome sequencing.

@ast

Predicting immunogenic tumour ...... trometry and exome sequencing.

@en

P1433

Q35453691-7968259B-A9BF-4469-AFFC-6D4D591ED659

P1476

Q35453691-5917119B-AA10-4343-9890-5AC258A1B2F8

P2093

Q35453691-05EA9FE2-2849-4457-9D97-F3B64C51353D

Q35453691-106163E6-D930-4D60-8CD5-3392D93809FF

Q35453691-236C2888-C8E8-4DE3-952F-738211D3DD1E

Q35453691-502DB54A-2EBA-4D64-8320-29D5A1EC6E3F

Q35453691-5177B157-1E16-41DD-9F89-0CE72BA2AFBC

Q35453691-51B596EA-D5B2-4FA0-81F4-D7E828C2A3D0

Q35453691-58CD386B-1627-4944-B196-DC1FFD70E87B

Q35453691-66459B51-0E73-4549-BA9C-319A50503B58

Q35453691-8E83A8FB-CEA2-4212-9921-79A66BB462DA

Q35453691-988AEDC2-9B4E-4088-8C07-ED0008BC37B6

P2888

Q35453691-672B011D-BA31-4272-B6C6-34FC1968FCB2

P304

Q35453691-175E3C49-B849-4D4E-BAC0-98A0BCECA5C0

P31

Q35453691-BE0AD431-9D9A-4D73-A017-DB9CE6BDFEE5

P356

Q35453691-B522DDB9-59B9-4549-B03F-AC9CB36EB104

P407

Q35453691-4E46CCD1-8AF3-45AA-89BE-FB6A1D557C61

P433

Q35453691-8D938B0F-6B8A-47D4-A772-008A6E81C28A

P478

Q35453691-E399198D-6D5B-4F41-8EF8-F467B2D26706

P50

Q35453691-6807C773-27D5-4725-A200-1ACD622CED2B

Q35453691-8E194332-1BC3-4F8D-903C-7F6A38B2C973

P577

Q35453691-82FF9C29-150E-4309-8086-E6AE4DEEFE56

P5875

Q35453691-C2CB3788-17CA-4DB3-9660-55281E04D34B

P6179

Q35453691-D8D05657-6725-40F4-898E-0AB20D663525

P698

Q35453691-2D3413A5-E13F-4155-B219-5EBF99AD2B54

P356

P1433

P1476

Predicting immunogenic tumour ...... ctrometry and exome sequencing

@en

P2093

Christian Franci

http://www.w3.org/2001/XMLSchema#string

Ira Mellman

http://www.w3.org/2001/XMLSchema#string

Jennie R Lill

http://www.w3.org/2001/XMLSchema#string

Joshua Tanguay

http://www.w3.org/2001/XMLSchema#string

Lélia Delamarre

http://www.w3.org/2001/XMLSchema#string

Mahesh Yadav

http://www.w3.org/2001/XMLSchema#string

Patrick Lupardus

http://www.w3.org/2001/XMLSchema#string

Qui T Phung

http://www.w3.org/2001/XMLSchema#string

Stephanie Bumbaca

http://www.w3.org/2001/XMLSchema#string

Suchit Jhunjhunwala

http://www.w3.org/2001/XMLSchema#string

P2888

P304

572-576

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE14001

http://www.w3.org/2001/XMLSchema#string

P407

P433

7528

http://www.w3.org/2001/XMLSchema#string

P478

515

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268874261

http://www.w3.org/2001/XMLSchema#string

P6179

1000934935

http://www.w3.org/2001/XMLSchema#string

P698

25428506

http://www.w3.org/2001/XMLSchema#string